Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

1. Pascual, A.M.
2. Téllez, N.
3. Boscá, I.
4. Mallada, J.
5. Belenguer, A.
6. Abellán, I.
7. Sempere, A.P.
8. Fernández, P.
9. Magraner, M.J.
10. Coret, F.
11. Sanz, M.A.
12. Montalbán, X.
13. Casanova, B.